Second Quarter 2026
Filed Aug 13, 2026Co-Diagnostics Reports Second Quarter 2026 Financial Results Advancing Commercialization Through FDA Submission, Global Clinical Progress and Manufacturing Expansion
Revenue was $ 166,131 and net loss narrowed to $ (6,283,786 ) from $ (7,730,117 ), while the Company advanced its FDA submission and international commercialization initiatives. However, revenue remained limited, the Company continued to report operating and net losses, and cash and cash equivalents were $ 3,649,632 as of June 30, 2026.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Product revenueGAAP | $ 166,131 | – | – |
| Total revenueGAAP | $ 166,131 | – | – |
| Cost of revenueGAAP | $ 45,303 | – | – |
| Gross profitGAAP | $ 120,828 | – | – |
| Sales and marketing expenseGAAP | $ 466,681 | – | – |
| General and administrative expenseGAAP | $ 1,500,803 | – | – |
| Research and development expenseGAAP | $ 4,152,287 | – | – |
| Depreciation and amortizationGAAP | $ 201,840 | – | – |
| Total operating expensesGAAP | $ 6,321,611 | – | – |
| Loss from operationsGAAP | $ (6,200,783 ) | – | – |
| Interest income, netGAAP | $ 17,493 | – | – |
| Realized gain on investmentsGAAP | - | – | – |
| Gain (loss) on remeasurement of acquisition contingenciesGAAP | $ (29,171 ) | – | – |
| Loss on equity method investment in joint venturesGAAP | $ (52,157 ) | – | – |
| Total other income (expense), netGAAP | $ (63,835 ) | – | – |
| Loss before income taxesGAAP | $ (6,264,618 ) | – | – |
| Income tax provisionGAAP | $ 19,168 | – | – |
| Net lossGAAP | $ (6,283,786 ) | – | – |
| Basic and diluted loss per common shareGAAP | $ (1.46 ) | – | – |
| Weighted average shares outstanding: Basic and Dilutedother | 4,309,997 | – | – |
| Comprehensive lossGAAP | $ (6,283,786 ) | – | – |
| Adjusted EBITDAnon-GAAP | $ (5,837,348 ) | – | – |
What drove it
- Revenue was primarily driven by higher product revenue.
- Operating expenses declined primarily due to lower general and administrative and research and development expenses, including reduced legal, personnel and stock-based compensation expenses.
- The Company completed clinical and analytical performance studies supporting its FDA 510(k) submission for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument.
- The Company submitted a 510(k) premarket notification, together with a concurrent CLIA Waiver by Application, to the U.S. Food and Drug Administration for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument.
- The Company advanced manufacturing and planned localized production in Saudi Arabia, initiated clinical performance studies in India for the CoSara PCR MTB test, and entered a distribution agreement covering Mexico.
- Vector Smart customer footprint expanded to 21 U.S. states, with four new mosquito abatement district laboratory installations completed during the quarter.
Concerns
- The Company reported a net loss of $ (6,283,786 ) and adjusted EBITDA of $ (5,837,348 ).
- Cash and cash equivalents totaled $ 3,649,632 as of June 30, 2026.
- The Co-Dx PCR platform has not been cleared or authorized by the FDA, is subject to review by the FDA and/or other regulatory bodies, and is not yet available for sale.
- The Company identified risks related to the timing and outcome of regulatory review, commercialization, manufacturing scale-up, market adoption, third-party dependence, international operations, and its ability to obtain additional capital when needed.
What to watch
- FDA review of the 510(k) premarket notification and concurrent CLIA Waiver by Application for the Co-Dx PCR Flu A/B & RSV test on the Co-Dx PCR Pro instrument.
- Progress of clinical performance studies in India for the CoSara PCR MTB test.
- Execution of localized manufacturing plans in Saudi Arabia and planned commercialization across the Middle East and North Africa.
- Commercial deployment under the Mexico distribution agreement and continued adoption of Vector Smart.
- Liquidity and the Company’s ability to obtain additional capital when needed.
Balance sheet and cash flow
- Cash and cash equivalents were $ 3,649,632 as of June 30, 2026, compared to $ 11,884,607 as of December 31, 2025.
- Accounts receivable, net were 52,059 as of June 30, 2026, compared to 190,375 as of December 31, 2025.
- Inventory, net was 841,669 as of June 30, 2026, compared to 992,397 as of December 31, 2025.
- Total current assets were 5,192,458 as of June 30, 2026, compared to 13,693,465 as of December 31, 2025.
- Property and equipment, net was 1,975,111 as of June 30, 2026, compared to 2,272,098 as of December 31, 2025.
- Intangible assets, net were 7,219,000 as of June 30, 2026 and December 31, 2025.
- Investment in joint ventures was 435,051 as of June 30, 2026, compared to 350,569 as of December 31, 2025.
- Total assets were $ 16,590,631 as of June 30, 2026, compared to $ 24,742,585 as of December 31, 2025.
- Total current liabilities were 2,863,395 as of June 30, 2026, compared to 3,539,620 as of December 31, 2025.
- Total long-term liabilities were 1,014,887 as of June 30, 2026, compared to 574,301 as of December 31, 2025.
- Total liabilities were 3,878,282 as of June 30, 2026, compared to 4,113,921 as of December 31, 2025.
- Total stockholders’ equity was 12,712,349 as of June 30, 2026, compared to 20,628,664 as of December 31, 2025.
- The Company strengthened the balance sheet through a $3.0 million private placement priced at-the-market under Nasdaq rules.
Analysis
Co-Diagnostics reported $ 166,131 of total revenue for the second quarter ended June 30, 2026, compared with $ 162,910 in the second quarter of 2025. The release attributes the increase to higher product revenue. Gross profit was $ 120,828 compared with $ 130,804, as cost of revenue was $ 45,303 compared with $ 32,106. The filing provides no sequential revenue or gross-profit comparison and does not report gross margin.
The loss profile improved from the prior-year quarter as total operating expenses were $ 6,321,611 versus $ 8,188,568 and loss from operations was $ (6,200,783 ) versus $ (8,057,764 ). The expense decline reflected lower general and administrative expense, research and development expense, sales and marketing expense, and depreciation and amortization. Net loss was $ (6,283,786 ), or $ (1.46 ) per basic and diluted share, compared with net loss of $ (7,730,117 ), or $ (7.00 ) per basic and diluted share. Adjusted EBITDA was $ (5,837,348 ) compared with $ (7,199,845 ).
The balance sheet remains a principal focus. Cash and cash equivalents were $ 3,649,632 at June 30, 2026, compared with $ 11,884,607 at December 31, 2025, while total assets were $ 16,590,631 compared with $ 24,742,585. The Company also cited a $3.0 million private placement priced at-the-market under Nasdaq rules. No operating cash flow, free cash flow, debt balance, share repurchase, or dividend information was reported in the release.
Operationally, the quarter centered on advancing the Co-Dx PCR platform toward commercialization rather than on material current revenue scale. The Company completed supporting clinical and analytical studies and submitted a 510(k) premarket notification with a concurrent CLIA Waiver by Application for its Flu A/B & RSV test. International initiatives included Saudi manufacturing plans, tuberculosis clinical studies in India, a Mexico distribution agreement, and continued CoSara development work. The platform is not cleared or authorized by the FDA and is not yet available for sale, making the regulatory review process, commercialization execution, and liquidity central items to monitor.
The filing provides no financial guidance and no prior-quarter financial comparison. It also does not disclose segment revenue, so the reported product revenue is the only disclosed revenue category. The quarter therefore shows lower operating losses and meaningful regulatory and commercial preparation, alongside limited reported revenue and continuing dependence on regulatory progress and additional-capital access.
Management, verbatim
Our second quarter marked a period of meaningful operational progress for Co-Diagnostics, as years of investment across our platform are illustrated by these tangible milestones. This progress was reflected across our regulatory, clinical and commercial priorities, including expanding our tuberculosis program in India and strengthening our international manufacturing and commercialization capabilities. More recently, we built on that momentum by submitting our FDA 510(k) application for the Co-Dx™ PCR Flu A/B & RSV upper respiratory multiplex test on the Co-Dx PCR Pro ® instrument. Together, these milestones reinforce that we are executing against our strategic priorities and advancing the platform toward commercialization.
Dwight Egan, Chief Executive Officer of Co-Diagnostics
Not in the filing
stated, not guessed- Gross margin
- Non-GAAP EPS
- Prior-quarter revenue, expense, profit, loss, EPS, and adjusted EBITDA comparisons
- Segment revenue and segment operating results
- Operating cash flow
- Free cash flow
- Debt balance
- Share repurchases
- Dividends
- Forward financial guidance
- Prior outlook for comparison
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.